By vgreene, 14 June, 2019 NTRK (nuerotrophic receptor tyrosine kinase) gene testing: to identify candidates for larotrectinib1,2
By vgreene, 14 June, 2019 DNA Mismatch Repair (MMR)/Microsatellite Instability (MSI) testing: of tumor status (if not previously done)1,2 [NCCN 2A] to identify CRC pts at high risk for Lynch syndrome and/or prognostic stratification;3 universal MMR or MSI testing recommended in al
By vgreene, 14 June, 2019 BRAF V600E mutational analysis:1-3 of the primary colorectal CAs and/or the metastasis to determine tumor gene status;1,2 [NCCN 2A] perform testing only in CLIA-certified "high-complexity" labs and on formalin-fixed paraffin-embedded tissue;1,2 perform in
By vgreene, 14 June, 2019 RAS (KRAS and NRAS) mutation testing:1-3 specifically KRAS condons 12 and 13 exon 2 mutation of the primary colorectal CAs and/or the metastasis to determine tumor gene status;1,2 [NCCN 2A] perform testing for KRAS, NRAS, and BRAF mutations only in CLIA-8